Rituximab for Relapsing Nephrotic Syndrome in Adults

Does rituximab, compared with placebo, prevent relapse in adult patients with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome?In this randomized clinical trial that included 66 adults with either frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome, rituximab treatment significantly improved the relapse-free rate at week 49 compared with placebo (87.4% vs 38.0%).In adult patients with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome, these findings support rituximab for reducing the relapse rate of nephrotic syndrome.

Corresponding Author: Yoshitaka Isaka, MD, PhD, Department of Nephrology, The University of Osaka Graduate School of Medicine, 2-2-D11, Yamada-oka, Suita, Osaka 565-0871, Japan (isaka@kid.med.osaka-u.ac.jp).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.